Table 4.

Multivariate Cox regression analysis on disease-specific survival

	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
All stages
Age ≥59 years	0.96	0.60–1.55	0.876	0.98	0.61–1.59	0.938
FIGO Stage III/IV	3.31	1.34–8.13	0.009	3.59	1.73–9.37	0.009
Grade III/undifferentiated	1.97	1.19–3.27	0.008	1.64	0.98–2.74	0.059
Non-serous tumor	0.67	0.41–1.12	0.125	0.63	0.38–1.05	0.078
Residual tumor	3.38	2.27–6.44	<0.001	3.01	1.82–4.96	<0.001
CD8+ T-lymphocytes high (OV)	0.36	0.22–0.59	<0.001
CD8+/FoxP3+ ratio high (OV)				0.53	0.32–0.85	0.009
Advanced stage only
Age ≥ 59 years	0.82	0.50–1.36	0.444	1.02	0.63–1.64	0.945	0.99	0.60–1.64	0.979
Grade III/undifferentiated	1.75	1.02–2.99	0.041	1.82	1.07–3.09	0.026	1.69	0.96–2.97	0.067
Non-serous tumor	0.76	0.44–1.30	0.309	0.77	0.44–1.33	0.346	0.72	0.42–1.23	0.229
Residual tumor	3.58	2.08–6.17	<0.001	2.41	1.50–3.88	<0.001	2.56	1.54–4.25	<0.001
CD8+ T-lymphocytes high (OV)	0.35	0.21–0.60	<0.001
CD45R0+ T-lymphocytes present (OV)				0.72	0.46–1.14	0.166
FoxP3+ T-lymphocytes present (OV)							0.55	0.34–0.88	0.013
Age ≥59 years	1.00	0.61–1.65	1.000	0.76	0.43–1.33	0.888	0.76	0.44–1.33	0.335
Grade III/undifferentiated	1.42	0.83–2.44	0.205	1.04	0.57–1.89	0.910	1.29	0.70–2.37	0.417
Non-serous tumor	0.76	0.44–1.30	0.318	0.60	0.34–1.06	0.078	0.66	0.37–1.20	0.177
Residual tumor	2.50	1.51–4.15	<0.001	2.63	1.41–4.90	0.002	2.74	1.46–5.15	0.002
CD8+/FoxP3+ ratio high (OV)	0.68	0.42–1.08	0.099
CD45R0+ T-lymphocytes present (OM)				0.69	0.43–1.08	0.106
FoxP3+ T-lymphocytes high (OM)							0.64	0.39–1.06	0.082

Analyses were performed stratified for type of chemotherapy. FIGO International Federation of Gynecology and Obstetrics, HR hazard ratio, CI confidence interval, OV ovarian-derived tumor tissue, OM omental metastasis

Bold signifies p < 0.05